• To find the highest tolerable dose of ABI-009 that can be given to patients with solid tumors. [ Time Frame: 14 Months ] [ Designated as safety issue: No ]
  

• The effect of the study drug on the tumor and how long it stays in the body will also be studied. [ Time Frame: 14 Months ] [ Designated as safety issue: No ]
  

Inclusion Criteria:

• Male and female patients with histologically or cytologically confirmed diagnosis of cancer which is not amenable to curative therapy. For the purpose of this study, advanced disease will be defined as metastatic disease or locally advanced disease that is surgically unresectable and considered unmanageable with standard therapies such as radiation or systemic therapies.
• Patients with advanced non-hematologic malignancies for whom no standard therapy exists.
• Measurable disease by RECIST or evaluable disease (e.g., bone metastasis, pleural effusion, ascites, or lesions which do not fulfill RECIST criteria for metastatic disease)
• Off all therapy (inclusive of investigational therapies) for at least 4 weeks prior to study drug administration OR off all daily or weekly therapy (inclusive of investigational therapies) for at least 2 weeks prior to study drug administration and without any side effects associated with these therapies.
• Female patients of child-bearing potential must have a negative serum pregnancy test within 7 days prior to first study drug administration and must agree to the use of a physical method of non-hormonal contraception while patient is participating in this study and at least 6 months following discontinuation of study drug.
• Female patients who are postmenopausal must have 12 months of amenorrhea, surgically sterile, or must agree to the use of a physical method of non-hormonal contraception while patient is participating in this study and at least 6 months following discontinuation of study drug.
• Male patients must be surgically sterile or agree to the use of a barrier method of contraception while patient is participating in this study and at least 6 months following discontinuation of study drug.
• Life expectancy of >/= 3 months.
• ECOG Performance Status of 0-2.
• Patients must be able to provide informed consent indicating knowledge of his/her disease process, the investigational nature of the therapy, alternatives, benefits, and risks including potential side effects.
• Age >/= 18 years of age.
• No major surgery within 4 weeks before treatment with ABI-009. (A biopsy is not considered major surgery).
• No chemotherapy, hormonal therapy, immunotherapy or radiotherapy within 4 weeks before treatment with ABI-009 (6 weeks for previous treatment with nitrosoureas, mitomycin, or extensive radiotherapy) and no immunosuppressive agents within 3 weeks before study entry (except corticosteroids used as antiemetics).
• No immunosuppressive agents within 3 weeks before study entry (except corticosteroids used as antiemetics).
• Required Initial Laboratory Data: Hemoglobin >/= 9.0 g/dL, WBC >/= 3,000/microliter, ANC >/= 1,500/microliter, Platelet count >/= 100,000/microliter, Total Bilirubin </= ULN, SGOT (AST) </= 1.5 x upper limits of normal, SGPT (ALT) </= 1.5 x upper limits of normal, Serum Cholesterol </= 350 mg/dL, Serum Triglyceride </= 300 mg/dL.
• Adequate renal function with serum creatinine </= 1.5 mg/dL and/or creatinine clearance (Cockcroft formula) >/= 60 mL/min.
• No active alcohol abuse, drug addiction, or psychotic disorders.
• No known concomitant genetic or acquired immunosuppressive diseases (such as AIDS).
• If obese, a patient must be treated with doses calculated using his/her actual BSA (The physician must be comfortable treating at the full BSA dose regardless of BSA).

Exclusion Criteria:

• Pregnant or nursing women.
• History of allergic reactions attributed to compounds of similar chemical or biologic composition including macrolide (e.g. azithromycin, clarithromycin, dirithromycin, and erythromycin) and ketolide antibiotics.
• Patients have not recovered from adverse affects of radiation therapy or investigational agent within previous 28 days.
• Uncontrolled intercurrent illness that in the opinion of the investigator would limit compliance and tolerance to study requirements (eg: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, diabetes, uncontrolled hypertension, coronary artery disease, or psychiatric illness/social situations).
• Patients with known brain metastases or leptomeningeal tumor involvement should be excluded from this clinical trial because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
• Receiving any of the following: concomitant antitumor therapy or inhibitors of CYP3A4.